AMSTERDAM [Netherlands], Union Health Secretary Apoorva Chandra on Wednesday visited the manufacturing unit of Bilthoven Biologicals in Utrecht, Netherlands, a branch of Pune-based Serum Institute of India that manufactures Oral Poly Vaccine (OPV). We have to visit an Indian company which is manufacturing the vaccine in Bilthoven, New Zealand,” Chandra said. Earlier in the day, an agreement was signed under which Bharat Biotech will collaborate with Netherlands-based Bilthoven Biologicals BV, a wholly owned subsidiary of the Serum Institute of India, and supply Ora to India and globally. Will purchase pharmaceutical substances for the manufacture of polio vaccines. "This will contribute to the safety of oral polio vaccines," the Ministry of Health and Family Welfare said in a press release. With this partnership, BBIL's capacity to manufacture Oral Polio Vaccine (OPV) has increased to 500 million doses every year.The press release further states that Serum Institute of India had acquired this company about 10 years ago and has grown it. Its capacity will increase from 1 crore vaccines per year to not more than 50 crore vaccines per year. “This company has the capacity,” he said, referring to the agreement. To provide oral polio vaccines to India which will then be bottled in India in collaboration with Serum Institute of India and Aaragh Biotech.The Health Secretary earlier said, "Till now the raw material for oral polio vaccines was obtained only from an Indonesia-based company. So it will be a matter of pride for us that an Indian company will supply oral vaccines to India in future." On the day the Union Health Secretary met CEO Juergen Quick and Poonawalla Science Park (PSP) CEO Jeff de Klerk in Bilthoven on EU pandemic preparedness, partnerships and collaboration on vaccine production, he also met senior management and briefed them. Information about various manufacturing units was given. Of convenience. A detailed presentation was given on their future manufacturing plans. Bilthoven Biologicals BV manufactures pharmaceutica products such as polio, diphtheria-tetanus-polio and tetanus alone vaccines with Bacillus Calmette-Guérin (BCG).